Jacob Rotmensch
AuthID: R-00K-25X
1
TITLE: A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study Full Text
AUTHORS: David L Tait; John A Blessing; James S Hoffman; Kathleen N Moore; Nick M Spirtos; Jason A Lachance; Jacob Rotmensch; David Scott Miller ;
PUBLISHED: 2011, SOURCE: Gynecologic Oncology, VOLUME: 121, ISSUE: 1
AUTHORS: David L Tait; John A Blessing; James S Hoffman; Kathleen N Moore; Nick M Spirtos; Jason A Lachance; Jacob Rotmensch; David Scott Miller ;
PUBLISHED: 2011, SOURCE: Gynecologic Oncology, VOLUME: 121, ISSUE: 1
2
TITLE: A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: A gynecologic oncology group trial. A Gynecologic Oncology Group Trial
AUTHORS: Russell J Schilder; John A Blessing; Mark S Shahin; David Scott Miller ; Krishnansu Sujata Tewari; Carolyn Y Muller; David P Warshal; Scott McMeekin; Jacob Rotmensch;
PUBLISHED: 2010, SOURCE: International Journal of Gynecological Cancer, VOLUME: 20, ISSUE: 7
AUTHORS: Russell J Schilder; John A Blessing; Mark S Shahin; David Scott Miller ; Krishnansu Sujata Tewari; Carolyn Y Muller; David P Warshal; Scott McMeekin; Jacob Rotmensch;
PUBLISHED: 2010, SOURCE: International Journal of Gynecological Cancer, VOLUME: 20, ISSUE: 7
3
TITLE: Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: A Gynecologic Oncology Group study Full Text
AUTHORS: John H Edmonson; John A Blessing; Jonathan A Cosin; David Scott Miller ; David E Cohn; Jacob Rotmensch;
PUBLISHED: 2002, SOURCE: Gynecologic Oncology, VOLUME: 85, ISSUE: 3
AUTHORS: John H Edmonson; John A Blessing; Jonathan A Cosin; David Scott Miller ; David E Cohn; Jacob Rotmensch;
PUBLISHED: 2002, SOURCE: Gynecologic Oncology, VOLUME: 85, ISSUE: 3
